Search clinical trials for: sequential DEB-BACE and Arotinib and Tirelizumab

Total 5483 results

Gang Wu

Not yet recruiting

Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

Carcinoma, Non-Small Cell Lung
Ningbo Medical Center Lihuili Hospital

Recruiting

The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

Non-Small Cell Lung Cancer

China
Robert Wood Johnson Foundation

Completed

Using Tailored Emails to Motivate Healthy Behavior Among Employees

Health Behavior
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Instituto de Investigación Sanitaria de la Fundación...

Completed

Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC

Hepatocellular Carcinoma

Spain
Surefire Medical, Inc.

Terminated

DEB-TACE for Hepatocellular Carcinoma (QED)

Hepatocellular Carcinoma

United States
RenJi Hospital
Boston Scientific Corporation

Not yet recruiting

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

Liver Cancer
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments

Carcinoma, Non-Small-Cell Lung
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma

China
Peking University Cancer Hospital & Institute

Not yet recruiting

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

HCC | Regorafenib | Transarterial Chemoembolization | Hepatic Arterial Infusion Chemotherapy
Johannes Gutenberg University Mainz

Unknown

Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).

Intrahepatic Cholangiocellular Carcinoma

Germany
Johannes Gutenberg University Mainz

Completed

Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).

Hepatocellular Carcinoma
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases

Colorectal Liver Metastases (CRCLM)

China
Daping Hospital and the Research Institute of Surgery...

Recruiting

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Gastric Cancer | Rectal Cancer | Chemotherapy Effect | Radiotherapy | Immunotherapy

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Hepatocellular Carcinoma Non-resectable

China
Leonardo Bolognese, MD

Terminated

A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation (ELICOPTER)

Myocardial Ischemia

Italy
Zhongda Hospital

Recruiting

TACE Combined With Penpulimab and Anlotinib for Advanced HCC

Hepatocellular Carcinoma

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Xuhua Duan

Recruiting

DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial

HCC

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Apatinib | PD-1 Antibody | Transarterial Chemoembolization

China
Ji Yongling

Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer
ZhuHai Cardionovum Medical Device Co., Ltd.
R&G Pharma Studies Co.,Ltd.

Completed

Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease

Coronary Stenosis

China
Tongji Hospital

Recruiting

A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC (CCGLC-005)

Intrahepatic Cholangiocarcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

China
Surefire Medical, Inc.

Terminated

Surefire Precision Infusion System Registry

Hepatocellular Carcinoma

United States
Second Affiliated Hospital of Guangzhou Medical...
First People's Hospital of Foshan; Huizhou Municipal Central Hospital; Zhongshan... and other collaborators

Completed

Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Tongji Hospital

Recruiting

PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer (CCGLC-004)

Hepatocellular Carcinoma

China
University of Texas Southwestern Medical Center

Completed

A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin

Hepatocellular Cancer

United States
Terumo Europe N.V.

Completed

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

Hepatocellular Carcinoma

Belgium, France
Guangxi Medical University

Completed

HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC (FRONT-1)

Liver Cancer

China
Guangxi Medical University

Recruiting

DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Unknown

TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

Carcinoma, Hepatocellular

China
Helsinki University Central Hospital
University of Helsinki

Recruiting

Pre-eclampsia and Future Cardiovascular Health: An Underused Opportunity to Improve Family Health (FINNCARE)

Cardiovascular Diseases | Pre-Eclampsia | Cardiovascular Risk Factor | Gestational Hypertension

Finland
Singapore General Hospital

Completed

Investigating the Safety and Efficacy of the Treatment With Luminor DCB and Angiolite DES of iVascular in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia (MERLION)

Critical Limb Ischemia

Singapore
Jinglong Chen

Recruiting

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Hepatocellular Carcinoma

China
First Affiliated Hospital Xi'an Jiaotong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (ALTER-H-004)

Hepatocellular Carcinoma | Anlotinib | TACE

China
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
US Department of Veterans Affairs

Completed

Internet-based Diabetes Education and Case Management

Hypertension | Diabetes Mellitus

United States
Fudan University

Recruiting

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Malignant Brain Tumor | Brain Stem Glioma,

France
University of Pisa
Azienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaborators

Recruiting

Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC (SEASON-HCC)

HCC

Italy
Zhejiang Cancer Hospital

Recruiting

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

Extensive Stage Small Cell Lung Cancer

China
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE)

Carcinoma, Hepatocellular

Italy
University Hospital, Ghent

Terminated

Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) (TRACE)

Hepatocellular Carcinoma

Belgium
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
Renmin Hospital of Wuhan University

Completed

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (RENMIN-213)

Advanced Gastric Adenocarcinoma

China
Zhongda Hospital

Recruiting

DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC

Hepatocellular Carcinoma

China

3

Subscribe